Long-Term Follow-Up of Patients Who Have Received An Autologous Antigen-Specific Chimeric Antigen Receptor T Regulatory Cell Therapy (CAR-Treg therapy, TX200-TR101) In A Prior Clinical study

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-512580-31-00

Acronym

TX200-KT03

Enrollment

Registered

2024-07-31

Start date

2023-07-21

Completion date

Unknown

Last updated

2025-06-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Kidney Transplant Rejection

Brief summary

Overall survival, Indicence and grade of Serious Adverse Events

Detailed description

Incidence of immune-mediated rejection in terms of BCAR episodes according to the Banff criteria (including type, severity and timing), Incidence of graft loss due to rejection, Incidence and severity of chronic graft dysfunction, as measured by eGFR

Interventions

DRUGTX200-TR101

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Overall survival, Indicence and grade of Serious Adverse Events	—

Secondary

Measure	Time frame
Incidence of immune-mediated rejection in terms of BCAR episodes according to the Banff criteria (including type, severity and timing), Incidence of graft loss due to rejection, Incidence and severity of chronic graft dysfunction, as measured by eGFR	—

Countries

Belgium, Netherlands

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026